Hikma epinephrine nasal spray filings accepted for review in US, Europe and UK
AI Summary- Hikma submitted its epinephrine nasal spray for regulatory review across major markets.
- The FDA accepted Hikma's New Drug Application under the 505(b)(2) pathway.
- Hikma also filed in Canada and plans further submissions beyond the initial markets.